Reduced FXR expression or altered activity contributes to the pathogenesis of IBD, CRC, and GEAC (28, 89, 90), positioning FXR as a potential tumor suppressor in the gastrointestinal tract (28, 90). Here, NR1H4 is linked to colorectal carcinoma.